Targeting Chelatable Iron as a Therapeutic Modality in Parkinson's Disease. Devos D; Moreau C; Devedjian JC; Kluza J; Petrault M; Laloux C; Jonneaux A; Ryckewaert G; Garcon G; Rouaix N; Duhamel A; Jissendi P; Dujardin K; Auger F; Ravasi L; Hopes L; Grolez G; Firdaus W; Sablonniere B; Strubi-Vuillaume I; Zahr N; Destee A; Corvol JC; Poltl D; Leist M; Rose C; Defebvre L; Marchetti P; Cabantchik ZI; and Bordet R Antioxid. Redox Signal., 21:195-210, 2014.
Targeting Chelatable Iron as a Therapeutic Modality in Parkinson's Disease [link]Paper  doi  bibtex   
@article{devos_d_targeting_2014,
title = {Targeting Chelatable Iron as a Therapeutic Modality in Parkinson's Disease},
volume = {21},
issn = {1523-0864},
url = {http://www.ncbi.nlm.nih.gov/pubmed/24251381},
DOI = {10.1089/ars.2013.5593},
Language = {English},
Journal = {Antioxid. Redox Signal.},
author = {{Devos D} and {Moreau C} and {Devedjian JC} and {Kluza J} and {Petrault M} and {Laloux C} and {Jonneaux A} and {Ryckewaert G} and {Garcon G} and {Rouaix N} and {Duhamel A} and {Jissendi P} and {Dujardin K} and {Auger F} and {Ravasi L} and {Hopes L} and {Grolez G} and {Firdaus W} and {Sablonniere B} and {Strubi-Vuillaume I} and {Zahr N} and {Destee A} and {Corvol JC} and {Poltl D} and {Leist M} and {Rose C} and {Defebvre L} and {Marchetti P} and {Cabantchik ZI} and {Bordet R}},
year = {2014},
keywords = {Animals, Cell Line, Combined Modality Therapy, Disease Models, Animal, Double-Blind Method, Humans, Iron/metabolism*, Iron Chelating Agents/administration & dosage, Iron Chelating Agents/therapeutic use*, Male, Mice, Mice, Inbred C57BL, Motor Activity/drug effects, Oxidative Stress/drug effects, Parkinson Disease/drug therapy*, Parkinson Disease/metabolism*, Pilot Projects, Pyridones/administration & dosage, Pyridones/pharmacology, Pyridones/therapeutic use*},
pages = {195-210}
}
Downloads: 0